Valeritas touted real-world data from 3 separate studies of its V-Go insulin delivery system showcasing the device’s utility and effectiveness.
V-Go is a disposable, wearable insulin delivery device designed to deliver a preset dosage continually over 24 hours and on-demand doses during meals.
The 1st study looked at 153 patients and how they fared switching to the V-Go system from either multiple daily insulin injections, long-acting basal insulin therapy or no treatment. Each cohort showed improvement in glycemic control on V-Go through several follow-ups, and the group that was previously on insulin injections needed less with the company’s device.
In the 2nd study, researchers looked at the safety and efficacy of V-Go in 21 patients in 2 groups. Some were adults with latent autoimmune diabetes and others had Type I diabetes. Both experienced elevated blood glucose levels and had been treated with the standard of care – multiple daily insulin injections. Patients in both arms of the study experienced big reductions in blood glucose levels and lower insulin requirements, Valeritas said.
For the 3rd study, researchers gathered data from 2 patients over age 65 who had poorly controlled Type II diabetes. They switched from daily insulin injections to V-Go and showed improved glycemic control with lower daily insulin needs.
"In each analysis, there was a statistically significant reduction in [blood glucose levels] and lowering of daily insulin needs," Valeritas CEO Kristine Peterson said in prepared remarks. "We are also particularly encouraged since these data are shown in a real-world setting."
In March, Valeritas tabled plans for a $75 million initial public offering.
